Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS) - Université de Lorraine Access content directly
Journal Articles American Journal of Hematology Year : 2015

Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS)

Abstract

We report our experience on bendamustine and rituximab (BR) combination in 26 patients with chronic lymphocytic leukemia (CLL) complicated by autoimmune hemolytic anemia (AIHA). At the time of BR initiation, 88% of the patients had already been treated for AIHA and CLL was progressive regardless of AIHA in all patients but one. Overall response rates were 81% for AIHA and 77% for CLL. Median time to next treatment was 28.3 months and 26.2 months for AIHA and CLL, respectively. BR therapy may represent a good and safe therapeutic option in this setting where adequate control of CLL seems important for long-term AIHA response. Am. J. Hematol. 90:204–207, 2015.

Dates and versions

hal-01667670 , version 1 (19-12-2017)

Identifiers

Cite

Anne Quinquenel, Christophe Willekens, Jehan Dupuis, Bruno Royer, Loic Ysebaert, et al.. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: A multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS). American Journal of Hematology, 2015, 90 (3), pp.204 - 207. ⟨10.1002/ajh.23909⟩. ⟨hal-01667670⟩
74 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More